inno.N will accelerate the research of new anticancer drugs using big data at the National Cancer Center Cancer and Jeonbuk National University Hospital.

The company said Wednesday that it plans to use the CONNECT platform, a cancer big data library, to classify target patients, develop biomarkers, select clinical trial agencies, and establish clinical development strategies.

The CONNECT platform is a multi-center clinical library platform that collects cancer clinical data produced by 11 medical institutions, including the National Cancer Center. The platform collects data on 10 cancer types, such as breast, thyroid, ovarian, and lung cancer, for research purposes.

Inno.N has selected IN-A103, a new selective RET inhibitor series target anticancer drug, and IN-A008, and a next-generation EGFR inhibitor series target anticancer drug, as the first two drugs that will use the CONNECT platform. The company said it started to use cancer big data to improve the accuracy and efficiency of research.

"During the clinical development stage of anticancer drugs, the definition of the patient group and patient recruitment determine the success or failure and the speed of research and development," the company said. "By identifying the characteristics of local patients with big data, it is possible to design optimal clinical trials, discover new cancer-related mutant genes and biomarkers, and conduct additional researches based on such findings."

Song Geun-seok, inno.N’s executive director for R&D, also said, "The company expects that the use of cancer big data will improve research accuracy and efficiency, enhancing our ability to develop new anticancer drugs on higher levels."